ArticleJournal of hepatocellular carcinoma2026
Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Sintilimab combined with bevacizumab (Sinti-Bev) is recommended as first-line treatment for unresectable hepatocellular carcinoma (uHCC) in China. However, the IMbrave150 and ORIENT-32 trials reported treatment-related adverse events (TRAEs) leading to bevacizumab interruption or discontinuation. Therefore, we aimed to explore the clinical impact of low-dose bevacizumab combined with sintilimab as a first-line therapy in patients with uHCC. Patients and Methods: A total of 85 patients who received Sinti-Bev as first-line therapy were retrospectively analyzed. Patients were stratified into low-dose (7.5 mg/kg, n=47) and high-dose (15 mg/kg, n=38) groups according to bevacizumab dosage. Antitumor efficacy, TRAEs incidence, and treatment duration were compared between groups. Inverse probability of treatment weighting (IPTW) was applied to balance baseline covariates. Results: In our study, although 91.8% of patients received Sinti-Bev combined with transarterial therapy (TAT), there was no significant difference in the number of TAT between groups. The low-dose group did not show significantly shorter progression-free survival (PFS: 9.4 vs.10.5 months, P = 0.837) and objective response rate (ORR: 61.70% vs. 63.16%, P = 0.890) compared with the high-dose group. Nevertheless, the overall survival (OS) rates in the low-dose group were numerically higher than those in the high-dose group (6/12/18 months: 94%/77%/55% vs. 91%/71%/48%). Post-IPTW analyses yielded consistent findings. Importantly, the incidence of esophagogastric variceal (EGV) bleeding was numerically lower in the low-dose group (10.6% vs. 21.1%), with fewer grade ≥3 bleeding events (6.38% vs. 18.42%). After IPTW adjustment, the median treatment duration was approximately 2.5 months longer in the low-dose group (12.0 vs. 9.5 months). Conclusion: Compared to high-dose bevacizumab combined with sintilimab, the low-dose regimen showed no significant differences in PFS, OS, or ORR, while improving safety and treatment continuity. Low-dose bevacizumab may serve as a safer alternative dose for uHCC patients with increased bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.